NEW YORK (TheStreet) -- RATINGS CHANGES

Edwards Lifesciences (EW) was upgraded at J.P. Morgan to overweight from neutral. Twelve-month price target is $155. The long-term story is more than intact, stronger today than it was two months ago, as analysts' confidence in the conversion of the SAVR market (surgical valve replacement) to TAVR (transcatheter replacement) increased significantly at this year's annual meeting of the American College of Cardiology, J.P. Morgan said.

Gap (GPS) was downgraded at FBR Capital Markets to market perform from outperform. Twelve-month price target is $40. Company will likely see lower margins, FBR Capital Markets said.

IBM (IBM) was upgraded to buy at TheStreet Ratings. You can view the full analysis from the report here: IBM Ratings Report.

Infinera (INFN) was initiated with a buy rating at Deutsche Bank. Analysts have a differentiated long view, noting INFN as a pure play on the "Cloud Optical" opportunity -- i.e., 40/100G+ optical data-center interconnects for Web 2.0 and Cloud seeing mid double-digit capex spending CAGR, Deutsche Bank said.

ING (ING) was downgraded to sell at TheStreet Ratings. You can view the full analysis from the report here: ING Ratings Report.

Juniper (JNPR) was upgraded at Bank of America/Merrill to buy from neutral. Twelve-month price target is $34. New products should drive growth in the coming quarters, Bank of America/Merrill Lynch said.

If you liked this article you might like

Kraft Heinz's New CFO Is Just 29

This Is How to Avoid Becoming Amazon Roadkill

How Long Can This Rally Run?: Cramer's 'Mad Money' Recap (Monday 9/19/17)

Cramer: How to Avoid Being Amazon Roadkill

Analysts Wrong on iPhone; Retail Not Going Away: Best of Cramer